Skip to content

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05023993
Enrollment
20
Registered
2021-08-27
Start date
2022-06-23
Completion date
2026-09-21
Last updated
2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Prediabetes

Brief summary

This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.

Detailed description

PRIMARY OBJECTIVE: I. Evaluate the feasibility of conducting a home exercise and nutrition intervention in childhood cancer survivors (CCS) with a history of prediabetes. EXPLORATORY OBJECTIVES: I. Describe the association between patient demographics and treatment exposures and subsequent hyperglycemia and skeletal muscle health in childhood cancer survivors. II. Describe the effect of exercise with or without nicotinamide riboside (NR) on hyperglycemia and skeletal muscle health in CCS with a history of prediabetes. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks. ARM II: Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside orally (PO) daily for 6 weeks.

Interventions

OTHERExercise Intervention

Complete home exercise

DIETARY_SUPPLEMENTNicotinamide Riboside

Given PO

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
City of Hope Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* History of childhood cancer * History of prediabetes (HbA1c 5.7-6.4%) * In remission at time of enrollment * Time between completion of cancer-directed therapy and study entry: \>= 6 months * At least 18 years of age at time of enrollment * Able to access online exercise program at home * Ability to tolerate the prescribed resistance exercise program * English-speaking * Able to understand and sign the study specific informed consent form (ICF)

Exclusion criteria

* Taking a nicotinamide adenine dinucleotide (NAD)+ precursor in the two weeks prior to enrollment * Currently taking medication for hyperglycemia or diabetes * Females who are pregnant or planning to become pregnant * Currently recovering from an injury * Contraindication to magnetic resonance imaging (MRI) * Pacemaker

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS)Up to 6 weeksThe current protocol will be considered feasible if: 1. \>= 50% of eligible patients that are approached for participation enroll onto the study, 2. \>= 70% of enrolled participants successfully complete all study assessments (i.e. physical function tests, blood draw, imaging, and questionnaires at baseline and 6 weeks, and 3. Enrolled participants demonstrate \>= 70% compliance with prescribed exercise and nicotinamide riboside. Feasibility measures 2 and 3 will be assessed for the entire group of 20 subjects as a whole.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026